1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > ReGenX Biosciences, LLC - Product Pipeline Review - 2014

ReGenX Biosciences, LLC - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 35 pages

ReGenX Biosciences, LLC - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘ReGenX Biosciences, LLC - Product Pipeline Review - 2014’, provides an overview of the ReGenX Biosciences, LLC’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ReGenX Biosciences, LLC’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ReGenX Biosciences, LLC including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ReGenX Biosciences, LLC’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ReGenX Biosciences, LLC’s pipeline products

Reasons to buy

- Evaluate ReGenX Biosciences, LLC’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ReGenX Biosciences, LLC in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ReGenX Biosciences, LLC’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ReGenX Biosciences, LLC and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ReGenX Biosciences, LLC
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ReGenX Biosciences, LLC and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

ReGenX Biosciences, LLC - Product Pipeline Review - 2014
Table of Contents
ReGenX Biosciences, LLC Snapshot 5
ReGenX Biosciences, LLC Overview 5
Key Information 5
Key Facts 5
ReGenX Biosciences, LLC - Research and Development Overview 6
Key Therapeutic Areas 6
ReGenX Biosciences, LLC - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
ReGenX Biosciences, LLC - Pipeline Products Glance 14
ReGenX Biosciences, LLC - Clinical Stage Pipeline Products 14
Phase I Products/Combination Treatment Modalities 14
ReGenX Biosciences, LLC - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
ReGenX Biosciences, LLC - Drug Profiles 16
Gene Therapy to Activate Arylsulfatase A for Metachromatic Leukodystrophy 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Gene Therapy to Activate Factor IX for Hemophilia B 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Gene Therapy to Activate Tripeptidyl Peptidase 1 for Batten Disease 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
AP-22594 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Gene Therapy for Alzheimer's Disease 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Gene Therapy for Wet Age-Related Macular Degeneration 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Gene Therapy to Activate Arylsulfatase B for Maroteaux-Lamy Syndrome 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Gene Therapy to Activate Iduronidase for Hurler Syndrome 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Gene Therapy to Activate LDL Receptor for Homozygous Familial Hypercholesterolemia 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis (LCA) 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ReGenX Biosciences, LLC - Pipeline Analysis 28
ReGenX Biosciences, LLC - Pipeline Products by Target 28
ReGenX Biosciences, LLC - Pipeline Products by Route of Administration 29
ReGenX Biosciences, LLC - Pipeline Products by Molecule Type 30
ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action 31
ReGenX Biosciences, LLC - Recent Pipeline Updates 32
ReGenX Biosciences, LLC - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables

ReGenX Biosciences, LLC, Key Information 5
ReGenX Biosciences, LLC, Key Facts 5
ReGenX Biosciences, LLC - Pipeline by Indication, 2014 7
ReGenX Biosciences, LLC - Pipeline by Stage of Development, 2014 8
ReGenX Biosciences, LLC - Monotherapy Products in Pipeline, 2014 9
ReGenX Biosciences, LLC - Partnered Products in Pipeline, 2014 10
ReGenX Biosciences, LLC - Partnered Products/ Combination Treatment Modalities, 2014 11
ReGenX Biosciences, LLC - Out-Licensed Products in Pipeline, 2014 12
ReGenX Biosciences, LLC - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
ReGenX Biosciences, LLC - Phase I, 2014 14
ReGenX Biosciences, LLC - Preclinical, 2014 15
ReGenX Biosciences, LLC - Pipeline by Target, 2014 28
ReGenX Biosciences, LLC - Pipeline by Route of Administration, 2014 29
ReGenX Biosciences, LLC - Pipeline by Molecule Type, 2014 30
ReGenX Biosciences, LLC - Pipeline Products by Mechanism of Action, 2014 31
ReGenX Biosciences, LLC - Recent Pipeline Updates, 2014 32

List of Figures

ReGenX Biosciences, LLC - Pipeline by Top 10 Indication, 2014 7
ReGenX Biosciences, LLC - Pipeline by Stage of Development, 2014 8
ReGenX Biosciences, LLC - Monotherapy Products in Pipeline, 2014 9
ReGenX Biosciences, LLC - Out-Licensed Products in Pipeline, 2014 12
ReGenX Biosciences, LLC - Pipeline by Top 10 Target, 2014 28
ReGenX Biosciences, LLC - Pipeline by Top 10 Route of Administration, 2014 29
ReGenX Biosciences, LLC - Pipeline by Top 10 Molecule Type, 2014 30
ReGenX Biosciences, LLC - Pipeline Products by Top 10 Mechanism of Action, 2014 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.